


FORM PTO-1390 • U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE REV. 2/01T		CUSTOMER NO. 22,852 ATTORNEY'S DOCKET NUMBER  09707.0001
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>		U.S. APPLICATION NO.: 10/519,162 (If known, see 37CFR1.5)
INTERNATIONAL APPLICATION NO.  <b>PCT/JP2003/008134</b>	INTERNATIONAL FILING DATE  June 26, 2003	PRIORITY DATE CLAIMED  June 26, 2002
TITLE OF INVENTION <b>DRUG COMPOSITION CONTAINING NF-<math>\kappa</math>B INHIBITOR</b>		
APPLICANT(S) FOR DO/EO/US <b>1) Kazuo UMEZAWA; 2) Yohko KAWAI; 3) Ryouichi HORIE; 4) Toshiki WATANABE; 5) Masakazu TOI; 6) Gaku MATSUMOTO; 7) Yutaka Horiguchi; 8) Jun NAKASHIMA</b>		
Applicant(s) herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1.	<input type="checkbox"/>	This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.
2.	<input checked="" type="checkbox"/>	This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.
3.	<input type="checkbox"/>	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4.	<input type="checkbox"/>	The US has been elected by the expiration of 19 months from the priority date (Article 31).
5.	<input type="checkbox"/>	A copy of the International Application as filed (35 U.S.C. 371 (c)(2)).
	a. <input type="checkbox"/>	is attached hereto (required only if not communicated by the International Bureau.
	b. <input type="checkbox"/>	has been communicated by the International Bureau.
	c. <input type="checkbox"/>	is not required, as the application was filed with the United States Receiving Office (RO/US).
6.	<input type="checkbox"/>	An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).
	a. <input type="checkbox"/>	is attached hereto.
	b. <input type="checkbox"/>	has been previously submitted under 35 U.S.C. 154 (d)(4).
7.	<input type="checkbox"/>	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)).
	a. <input type="checkbox"/>	are attached hereto (required only if not communicated by the International Bureau).
	b. <input type="checkbox"/>	have been communicated by the International Bureau.
	c. <input type="checkbox"/>	have not been made; however, the time limit for making such amendments has NOT expired.
	d. <input type="checkbox"/>	have not been made and will not be made.
8.	<input type="checkbox"/>	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9.	<input type="checkbox"/>	An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10.	<input type="checkbox"/>	An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
Items 11 to 20 below concern document(s) or information included:		
11.	<input checked="" type="checkbox"/>	Information Disclosure Statement under 37 CFR 1.97 and 1.98
12.	<input type="checkbox"/>	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13.	<input type="checkbox"/>	A FIRST preliminary amendment.
14.	<input type="checkbox"/>	A SECOND or SUBSEQUENT preliminary amendment.
15.	<input type="checkbox"/>	A Substitute specification.
16.	<input type="checkbox"/>	A change of power of attorney and/or address letter.
17.	<input type="checkbox"/>	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.
18.	<input type="checkbox"/>	A second copy of the published international application under 35 U.S.C. 154 (d)(4).
19.	<input type="checkbox"/>	A second copy of the English language translation of the international application 35 U.S.C. 154 (d)(4).
20.	<input checked="" type="checkbox"/>	Other items or information:
	a. <input checked="" type="checkbox"/>	Copies of documents and translations cited on PTO/SB/08
	b. <input type="checkbox"/>	
	c. <input type="checkbox"/>	

U.S. APPLICATION NO. (If known, see 37CFR 1.5) <b>10/519,162</b>		INTERNATIONAL APPLICATION NO. <b>PCT/JP2003/008134</b>		ATTORNEY'S DOCKET NUMBER <b>09707.0001</b>	
21. <input type="checkbox"/> The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</b> <span style="float: right;"><b>\$300.00</b></span> National Stage Search Fee.....\$500.00  National Stage Examination Fee.....\$200.00  <div style="text-align: right;"><b>ENTER APPROPRIATE BASIC FEE AMOUNT = \$</b></div>				CALCULATIONS PTO USE ONLY	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	=		x \$50.00	\$	
Independent Claims	=		x \$200.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+\$360.00	\$	
<b>TOTAL OF THE ABOVE CALCULATIONS =</b>				\$	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	
<b>SUBTOTAL =</b>				\$	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest priority date (37 CFR 1.492(f)).				\$	
<b>TOTAL NATIONAL FEE =</b>				\$	
Fee for recording the enclosed assignment (37 CFR 1.21 (h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property.				\$	
<b>TOTAL FEES ENCLOSED =</b>				\$	
				Amount to be refunded:	\$
				charged:	\$
a. <input type="checkbox"/> A check in the amount of \$ _ to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>06/0916</u> . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. <b>Credit card information should not be included on this form.</b> Provide credit card information and authorization on PTO-2038.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.					
<b>SEND ALL CORRESPONDENCE TO:</b> Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P. 901 New York Avenue, N.W. Washington, D.C. 20001-4413					
DATED: June <u>1</u> , 2006				<div style="text-align: center;">             SIGNATURE            David W. Hill, Reg. No. 28,220            NAME/REGISTRATION NO.         </div>	

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: <b>Kazuo UMEZAWA et al.</b>	)	
	)	
Application No.: <b>10/519,162</b>	)	
	)	Group Art Unit: Not Yet
Filed: <b>December 23, 2004</b>	)	Assigned
	)	
National Stage of International Application No.	)	Examiner: Not Yet Assigned
<b>PCT/JP2003/008134</b> under 35 U.S.C. 371	)	
	)	
For: <b>DRUG COMPOSITION CONTAINING NF-</b>	)	
<b>κB INHIBITOR</b>	)	

**MAIL STOP PCT**  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§1.56 and 1.97(b), Applicants bring to the Examiner's attention the documents listed on attached Form PTO/SB/08. With the exception of the U.S. patent, a copy of each listed document is attached. Applicants respectfully request that the Examiner consider the documents listed on attached Form PTO/SB/08 and indicate that they were considered by making an appropriate notation on this form.

To the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

The following are listed on the accompanying PTO/SB/08 and are in a non-English language:

1. WO 01/12588. An English-language abstract of the document is found on the first page. In addition, it is believed that U.S. Patent No. 6,566,394 is an English language equivalent of this document.

2. First Office Action issued by Chinese Patent Office in counterpart Chinese application no. 03814974.5 on April 7, 2006. An English translation is provided.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents. Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: June 7, 2006

By: David W. Hill  
David W. Hill  
Reg. No. 28,220

<b>IDS Form PTO/SB/08: Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			<i>Application Number</i>	10/519,162	
			<i>Filing Date</i>	December 23, 2004	
			<i>First Named Inventor</i>	Kazuo UMEZAWA	
			<i>Art Unit</i>	Not Yet Assigned	
			<i>Examiner Name</i>	Not Yet Assigned	
Sheet	1	of	1	<i>Attorney Docket Number</i>	09707.0001

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. <sup>1</sup>	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> <i>(if known)</i>			
		6,566,394	05-20-2003	Takeuchi et al.	

**Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004**

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> <i>(if known)</i>				
		WO 01/12588	02-22-2001	Merican Corporation		Abstract

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
		Copy of First Office Action issued by Chinese Patent Office in counterpart Chinese application no. 03814974.5 on April 7, 2006.	yes

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.